Kidney transplant study aims to find safer drug combo

NCT ID NCT06374095

Ongoing Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at 75 kidney transplant patients to compare two different drug combinations given right after transplant. One group gets a single dose of RATG plus basiliximab, while the other gets seven doses of RATG plus basiliximab. The goal is to see which approach causes fewer side effects like low platelet or white blood cell counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Basiliximab and RATG (Thymoglobulin)
What this could lead to: If successful, this could help doctors choose a safer drug combination for kidney transplant patients, reducing side effects like low blood cell counts.
What could go wrong: This is a small, observational study with only 75 patients, so results may not apply to everyone. It compares existing drugs, not a new breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY REPLACEMENT

Contacts and locations

Locations

ASST HPG23 - Unità di Nefrologia

Bergamo, BG, 24127, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.